Em recrutamento
FASE
Número Europeu 2023-506668-15-00
M22-574 CERVINO
A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Detalhes
Destaques